The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
1990
DOI: 10.1038/jcbfm.1990.63
|View full text |Cite
|
Sign up to set email alerts
|

Protection by NMDA Antagonists against Selective Cell Loss following Transient Ischaemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

6
52
1

Year Published

1992
1992
2002
2002

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 159 publications
(59 citation statements)
references
References 35 publications
6
52
1
Order By: Relevance
“…In the present study, we chose to administer MK801 systemically with a relatively higher dose of 7.5 mg/mg, at which all the animals in MK801-treated group survived well during the 4 h period of observation. Furthermore, considering the 1 h plasma half-life time of MK801 in rats, 45 we treated the animals with MK801 repetitively before and after SCI, bilateral CAO with hypotension 67 ± 69 or vertebral artery occlusion in rats 70,71 pretreatment: 0.1 ± 10 mg/kg, iv/ip 67,71 neuronal damage and microglial activation 72 reduced microglial activation and neuronal death of CA1 72 or did not prevent neuronal damage 67,71 67,71,72 posttreatment: 0.1 ± 5.0 mg/kg, ip/iv, immediately 20 h after reperfusion 67,71 neuronal damage and working memory 70 no neuroprotection 67,68,71 or decreased cell loss within 5 h injection after ischemia 69 and injected the drug slowly (16 min/infusion). MK801 delivered in this way has been shown to produce neuroprotection in experimental cerebral ischemia.…”
Section: Discussionmentioning
confidence: 99%
“…In the present study, we chose to administer MK801 systemically with a relatively higher dose of 7.5 mg/mg, at which all the animals in MK801-treated group survived well during the 4 h period of observation. Furthermore, considering the 1 h plasma half-life time of MK801 in rats, 45 we treated the animals with MK801 repetitively before and after SCI, bilateral CAO with hypotension 67 ± 69 or vertebral artery occlusion in rats 70,71 pretreatment: 0.1 ± 10 mg/kg, iv/ip 67,71 neuronal damage and microglial activation 72 reduced microglial activation and neuronal death of CA1 72 or did not prevent neuronal damage 67,71 67,71,72 posttreatment: 0.1 ± 5.0 mg/kg, ip/iv, immediately 20 h after reperfusion 67,71 neuronal damage and working memory 70 no neuroprotection 67,68,71 or decreased cell loss within 5 h injection after ischemia 69 and injected the drug slowly (16 min/infusion). MK801 delivered in this way has been shown to produce neuroprotection in experimental cerebral ischemia.…”
Section: Discussionmentioning
confidence: 99%
“…The noncompetitive NMDA receptor antagonist MK-801 (Wong et aI., 1986) was able to reduce the postischemic calcium uptake by approximately 50%, which may explain its neuroprotective effect in some studies (Gill et aI., 1988;Rod and Auer, 1989;Gill and Woodruff, 1990;Swan and Meldrum, 1990). However, administration of the competitive non-NMDA receptor antagonist NBQX (Shear down et aI., 1990a) was able totally to block evoked calcium uptake due to a partial synaptic blockade, in the same dosages as it has been reported to offer powerful neuroprotection Sheardown et al, 1990a, b).…”
Section: Discussionmentioning
confidence: 99%
“…In our model, the critical postischemic period thus would be after 4-12 h of reflow. However, excitatory amino acid antagonists and VDCC blockers must be adminis tered no later than 1-2 h after the ischemic insult (Rod and Auer, 1989;Diemer et aI., 1990;Swan and Meldrum, 1990;Valentino et aI., 1991) in order to offer neuroprotection. This discrepancy may be due to the fact that in these studies, the drugs were not present in concentrations high enough to reduce calcium uptake during 4-12 h after ischemia.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…MK-801 has been shown to interfere with a vari ety of pathological processes. Besides its remark able beneficial effect on infarct size after permanent vascular occlusion (Ozyurt et aI., 1988;Park et aI., 1988;Dirnagl et aI., 1990), it reduces neuronal in jury after severe hyperglycemia (Papagapiou and Auer, 1990) and improves the survival ratio of py ramidal neurons in the CAl sector of hippocampus after brief periods of global ischemia (Gill et aI., 1988;Kass et aI., 1989;Swan and Meldrum, 1990), although the latter has been related mainly to its temperature-lowering effect (Buchan and Pulsinelli, 2 h MeA occlusion 1990; Corbett et aI., 1990). It inhibits spontaneous electrocortical activity in a dose-dependent way (Marquis et aI., 1989), and it suppresses cortical spreading depression induced by electrical stimula tion (Marrannes et aI., 1989).…”
Section: ��--------------------[mentioning
confidence: 99%